Program
Modified-release Calcifediol Capsule
Also written as “CTAP101 Capsules”, “CTAP101” and “CTAP101 30 μg capsules”.
Its studies are mostly in Renal Insufficiency, Chronic · Hyperparathyroidism, Secondary · Vitamin D Deficiency · COVID-19 · Breast Neoplasms, led by OPKO Health.
Furthest: phase 3, since Oct 11, 201010 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| OPKO Health | 101 open or running | phase 3since Oct 11, 2010 | Apr 23, 2009 | Oct 2027phase 2 · NCT07494045 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 23, 2009First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT00888069 · 28 enrolled · United States
- Oct 11, 2010Phase 3 study in Renal Insufficiency, ChronicNCT01219855 · 78 enrolled · United States
- Jul 23, 2012Phase 3 study in Renal Insufficiency, ChronicNCT01651000 · 213 enrolled · United States
- Oct 6, 2012Phase 3 study in Renal Insufficiency, ChronicNCT01704079 · 216 enrolled · United States
- Oct 22, 2014Phase 1 study in Breast NeoplasmsNCT02274623 · 33 enrolled · United States
- Oct 31, 2014Phase 3 study in Renal Insufficiency, ChronicNCT02282813 · 298 enrolled
- Aug 23, 2018Phase 1 study in Hyperparathyroidism, SecondaryNCT03660800 · 67 enrolled · United States
- Sep 15, 2020Phase 2 study in COVID-19NCT04551911 · 171 enrolled · United States
- Sep 13, 2022Phase 3 study in Vitamin D DeficiencyNCT05543928 · 2 enrolled · United States
- Mar 20, 2026Phase 2 study in Hyperparathyroidism, SecondaryNCT07494045 · 40 planned · United States
Ahead
- Oct 2027Primary completion: phase 2 study in Hyperparathyroidism, SecondaryNCT07494045
TargetBeta
VDR →read by rule
“Vitamin D receptor agonist”ChEMBL 37, by rule
Other programs on VDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| calcipotrienerule | LEO Pharma | phase 4 | 39 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07494045Hyperparathyroidism, Secondary · United States | 2 | Recruiting | Oct 2027 | 40 |
| NCT05543928Vitamin D Deficiency · United States | 3 | Terminated | Jun 19, 2024 | 2 |
| NCT04551911COVID-19 · United States | 2 | Completed | Oct 8, 2021 | 171 |
| NCT03660800Hyperparathyroidism, Secondary · United States | 1 | Completed | Oct 24, 2018 | 67 |
| NCT02282813Renal Insufficiency, Chronic | 3 | Completed | May 2015 | 298 |
| NCT02274623Breast Neoplasms · United States | 1 | Completed | Feb 27, 2017 | 33 |
| NCT01704079Renal Insufficiency, Chronic · United States | 3 | Completed | Aug 2014 | 216 |
| NCT01651000Renal Insufficiency, Chronic · United States | 3 | Completed | Jul 2014 | 213 |
| NCT01219855Renal Insufficiency, Chronic · United States | 3 | Completed | Nov 2011 | 78 |
| NCT00888069Renal Insufficiency, Chronic · United States | 1 | Completed | Nov 2009 | 28 |
How it is read
Names in the registry
- “CTAP101 Capsules”, 4 entries
- “CTAP101”, 2 entries
- “CTAP101 30 μg capsules”, 2 entries
- “Rayaldee”, 1 entry
- “Cohort 1 CTAP101 Capsules- 60µg”, 1 entry
Codes read as this program: CTAP101.
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 4 studies
- Hyperparathyroidism, Secondary, 2 studies
- Vitamin D Deficiency, 1 study
- COVID-19, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.